Cargando…

Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study

Interferon alpha (IFN-α) has been used as a maintenance therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM) patients. In this study, we combined GM-CSF with IFN-α in order to improve IFN tolerance in post-ASCT myeloma patients. Primary aims were to evaluate myelotoxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Salmasinia, Donya, Chang, Myron, Wingard, John R., Hou, Wei, Moreb, Jan S.
Formato: Texto
Lenguaje:English
Publicado: Libertas Academica 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999958/
https://www.ncbi.nlm.nih.gov/pubmed/21151584
http://dx.doi.org/10.4137/CMO.S6161
_version_ 1782193492287553536
author Salmasinia, Donya
Chang, Myron
Wingard, John R.
Hou, Wei
Moreb, Jan S.
author_facet Salmasinia, Donya
Chang, Myron
Wingard, John R.
Hou, Wei
Moreb, Jan S.
author_sort Salmasinia, Donya
collection PubMed
description Interferon alpha (IFN-α) has been used as a maintenance therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM) patients. In this study, we combined GM-CSF with IFN-α in order to improve IFN tolerance in post-ASCT myeloma patients. Primary aims were to evaluate myelotoxicity and effectiveness of this maintenance therapy. The treatment included 4 × 10(6) units of IFN-α and 125 μg/m(2) of GM-CSF given three times a week for twelve months. Twenty seven patients were enrolled within 120 days after ASCT. One patient discontinued treatment due to thrombocytopenia and seven others were taken off study due to flu-like symptoms and/or increase in liver enzymes. With a median follow-up of 45.5 months, the median overall survival was not reached while the median progression-free survival was 28 months. Eleven patients (42%) have remained in very good partial remission or complete remission since ASCT. In conclusion, our results demonstrate that maintenance with GM-CSF and IFN-α is safe and effective.
format Text
id pubmed-2999958
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-29999582010-12-13 Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study Salmasinia, Donya Chang, Myron Wingard, John R. Hou, Wei Moreb, Jan S. Clin Med Insights Oncol Original Research Interferon alpha (IFN-α) has been used as a maintenance therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM) patients. In this study, we combined GM-CSF with IFN-α in order to improve IFN tolerance in post-ASCT myeloma patients. Primary aims were to evaluate myelotoxicity and effectiveness of this maintenance therapy. The treatment included 4 × 10(6) units of IFN-α and 125 μg/m(2) of GM-CSF given three times a week for twelve months. Twenty seven patients were enrolled within 120 days after ASCT. One patient discontinued treatment due to thrombocytopenia and seven others were taken off study due to flu-like symptoms and/or increase in liver enzymes. With a median follow-up of 45.5 months, the median overall survival was not reached while the median progression-free survival was 28 months. Eleven patients (42%) have remained in very good partial remission or complete remission since ASCT. In conclusion, our results demonstrate that maintenance with GM-CSF and IFN-α is safe and effective. Libertas Academica 2010-11-16 /pmc/articles/PMC2999958/ /pubmed/21151584 http://dx.doi.org/10.4137/CMO.S6161 Text en © 2010 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Original Research
Salmasinia, Donya
Chang, Myron
Wingard, John R.
Hou, Wei
Moreb, Jan S.
Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study
title Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study
title_full Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study
title_fullStr Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study
title_full_unstemmed Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study
title_short Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study
title_sort combination of ifn-α/gm-csf as a maintenance therapy for multiple myeloma patients after autologous stem cell transplantation (asct): a prospective phase ii study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999958/
https://www.ncbi.nlm.nih.gov/pubmed/21151584
http://dx.doi.org/10.4137/CMO.S6161
work_keys_str_mv AT salmasiniadonya combinationofifnagmcsfasamaintenancetherapyformultiplemyelomapatientsafterautologousstemcelltransplantationasctaprospectivephaseiistudy
AT changmyron combinationofifnagmcsfasamaintenancetherapyformultiplemyelomapatientsafterautologousstemcelltransplantationasctaprospectivephaseiistudy
AT wingardjohnr combinationofifnagmcsfasamaintenancetherapyformultiplemyelomapatientsafterautologousstemcelltransplantationasctaprospectivephaseiistudy
AT houwei combinationofifnagmcsfasamaintenancetherapyformultiplemyelomapatientsafterautologousstemcelltransplantationasctaprospectivephaseiistudy
AT morebjans combinationofifnagmcsfasamaintenancetherapyformultiplemyelomapatientsafterautologousstemcelltransplantationasctaprospectivephaseiistudy